A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis [0.03%]
布鲁达利尤单抗(IL-17受体拮抗剂)治疗中重度斑块状银屑病的评述
Y Tong,A J Peranteau,Z Nawas et al.
Y Tong et al.
Psoriasis is a chronic immune-mediated inflammatory disease with epidermal hyperplasia that affects 2-3% of the population. Interleukin (IL)-17 signaling has a central role in its pathogenesis. Brodalumab is a monoclonal antibody that neutr...
Review
Skin therapy letter. 2017 Jan;22(1):1-6. DOI: 2017
Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis [0.03%]
关于艾芬博康唑10％溶液治疗甲癣的最新研究进展
A K Gupta,C Studholme
A K Gupta
Efinaconazole 10% nail solution is a novel topical antifungal drug for the treatment of onychomycosis. Two Phase III trials were completed using efinaconazole 10% nail solution, where 17.8% and 15.2% of patients achieved complete cure, and ...
A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis [0.03%]
针对中重度斑块状银屑病的抗白细胞介素-17A单克隆抗体伊克斯珠单抗（ixekizumab）的评述
A J Peranteau,A E Turkeltaub,Y Tong et al.
A J Peranteau et al.
Psoriasis is a multifactorial chronic skin disease that can have significant detrimental effects on patients' physical, mental, antibodypsychosocial wellbeing. Patients often suffer from a decreased quality of life along with numerous comor...
Review
Skin therapy letter. 2016 Nov;21(6):1-6. DOI: 2016
K Gleghorn,J Wilson,M Wilkerson
K Gleghorn
Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off...
Review
Skin therapy letter. 2016 Sep;21(5):5-7. DOI: 2016
S Humphrey,K Beleznay,J D A Beleznay
S Humphrey
The chin and jaw line are integral parts of an individual's aesthetic profile, and the presence of submental fat detracts from this and can lead to displeasure with one's facial appearance. While liposuction and cosmetic surgery are regarde...
S Holmes
S Holmes
Frontal fibrosing alopecia, described just over 20 years ago, has become one of the most frequently seen causes of scarring alopecia at many specialist hair clinics. Considered a clinical variant of lichen planopilaris (LPP), it has distinc...
A K Gupta,C Studholme
A K Gupta
Adalimumab (Humira®) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS). Results of two Phase III trials of adalimumab demonstra...
E Wong,A Kurian
E Wong
Topical calcineurin inhibitors (TCIs) have been proposed as an alternative, long-term treatment option to topical corticosteroids, without the side effects commonly associated with steroid use. Currently, TCIs are only approved for treatmen...
Review
Skin therapy letter. 2016 Jan;21(1):8-10. DOI: 2016
Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion [0.03%]
黄褐斑和炎性后色素沉着：管理更新与专家意见
B Sofen,G Prado,J Emer
B Sofen
Dyschromia is a leading cause for cosmetic consultation, especially in those with diverse skin types (mixture of ethnicities) and with the rise of non-core and untrained physicians performing cosmetic procedures. Melasma and post-inflammato...
Review
Skin therapy letter. 2016 Jan;21(1):1-7. DOI: 2016
Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis [0.03%]
5％塔伐硼oles溶液：治疗足趾甲癣的新 topical疗法
G Gupta,K A Foley,A K Gupta
G Gupta
Onychomycosis is a stubborn fungal infection of the nails that can be difficult to effectively manage. One of the challenges with topical therapies is penetrating the nail plate to reach the site of infection. As the first antifungal in a b...
Review
Skin therapy letter. 2015 Nov;20(6):6-9. DOI: 2015